Kindred Biosciences (NASDAQ: KIN) is a development-stage biopharmaceutical company focused on saving and improving the lives of pets by delivering the same kinds of safe and effective medicines that human family members enjoy.  The company’s strategy is to identify compounds and targets that have already demonstrated safety and efficacy in humans and to develop therapeutics based on these validated compounds and targets for dogs, cats, and horses.  Kindred Biosciences has a deep pipeline of novel drugs and biologics in development across many therapeutic classes. For more information, visit the company’s website at www.kindredbio.com